GHRP-6 is a first-generation synthetic hexapeptide ghrelin receptor agonist extensively studied for pituitary somatotroph stimulation, orexigenic hypothalamic signaling, and cytoprotective tissue models.
Scientific Profile & Research Key Points: GHRP-6
GHRP-6 is a first-generation synthetic hexapeptide ghrelin receptor agonist extensively studied for pituitary somatotroph stimulation, orexigenic hypothalamic signaling, and cytoprotective tissue models.
Active Batch Release Specifications (Lot SL-2026-126)
Analytical release verification for current GHRP-6 (5 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-126 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water (1.0–2.0 mL)
Temperature & Stability
Store lyophilized at -20°C protected from light; refrigerate solution at 2°C–8°C.
GHRP-6 — Technical Questions & Answers
What is the molar concentration when reconstituting GHRP-6 (5 mg) in 2.0 mL?
Reconstituting the full 5 mg vial of GHRP-6 (MW 873.01 g/mol) in 2.0 mL of diluent produces a 2.50 mg/mL stock solution — equivalent to approximately 2.86 mM (2,864 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does GHRP-6's counterion stoichiometry affect assay mass calculations?
GHRP-6 (CAS 87616-84-0, formula C46H56N12O6) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify GHRP-6 Lot SL-2026-126 and what pathway does it target?
Lot SL-2026-126 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 873.01 g/mol. In preclinical literature, GHRP-6 targets GHS-R1a (Ghrelin Receptor) & CD36 cytoprotective pathways (Bowers C.Y. et al., Endocrinology (1984) — Discovery and activity of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (PMID: 6323121)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
CJC-1295, Ipamorelin, and Sermorelin: GHRH Analogues vs Ghrelin Receptor Agonists
A deep dive into somatotropic axis stimulation. Comparing GHRH receptor binding, DAC modification kinetics, ghrelin/GHS-R1a agonism, and pulsatile growth hormone secretion.
Gonadorelin, HCG, HMG and Kisspeptin: Mapping the Hypothalamic-Pituitary-Gonadal Axis
A comparative map of the HPG axis: GnRH receptor agonism (Gonadorelin), LH receptor mimetics (HCG), combined FSH/LH activity (HMG), and upstream GPR54 activation (Kisspeptin-10).
Human Growth Hormone (191aa): Somatropin Structure, Isoforms, and SEC-HPLC Analysis
A deep analysis of authentic 191-amino acid Somatropin vs 192-amino acid Somatrem. Size-exclusion chromatography (SEC), deamidation artifacts, and mass confirmation.
Related GH Secretagogues & Growth Factors Compounds
View category →